Latest News

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Typically, we'll want...

Why Copart’s New Credit Facility Matters for Shareholders Copart (CPRT) has put a fresh US$1.25b unsecured revolving credit facility in place, replacing its prior agreement and extending available liquidity out to January 2031 with optional one year extensions. The new facility includes multi currency borrowing capacity, swingline and letter of credit sublimits, and dedicated sub facilities for its German, Spanish, and UK subsidiaries, which ties directly into Copart’s expansion focused...

Key Insights The considerable ownership by individual investors in YG Entertainment indicates that they collectively...

Lennox International (LII) has put another solid quarter on the board for FY 2025, with Q3 revenue of US$1.4 billion, basic EPS of US$7.00 and net income of US$245.8 million setting the tone for this earnings season update. The company has seen quarterly revenue move from US$1.5 billion in Q2 2025 to US$1.4 billion in Q3, while EPS has shifted from US$7.86 to US$7.00 over the same stretch. This gives investors a clean read on how the top and bottom line are tracking through the year. With...

Recently, Wall Street analysts issued a cautious outlook on Red Rock Resorts, pointing to revenue growth projections that trail the broader gaming and leisure sector and expectations for a tighter free cash flow margin. This skepticism, combined with analysts’ view that the company’s returns on capital are not improving, raises questions about how much its valuation can expand without a shift in fundamentals. Next, we’ll explore how this focus on slowing free cash flow momentum may influence...

Madrigal Pharmaceuticals recently reported that its liver disease drug Rezdiffra has reached over US$1.00 billion in annualized sales, while also signing an exclusive global license agreement with Pfizer for ervogastat, a clinical-stage DGAT-2 inhibitor to expand its MASH treatment pipeline. This combination of rapid commercial uptake for Rezdiffra and external pipeline expansion with Pfizer highlights how Madrigal is trying to build a broader franchise in liver disease treatments. We’ll now...

When close to half the companies in Korea have price-to-earnings ratios (or "P/E's") below 14x, you may consider JT...

Otis Worldwide (OTIS) opened FY 2025 with third quarter revenue of US$3.7b and basic EPS of US$0.96, alongside trailing 12 month revenue of US$14.3b and EPS of US$3.41 that frame how the latest print fits into the year so far. The company has seen quarterly revenue move from US$3.6b in Q3 2024 to US$3.7b in Q3 2025, while basic EPS shifted from US$1.35 to US$0.96 over the same period. This sets up a picture where top line scale holds steady, and margins do more of the talking for...

Enova International's FY 2025 Earnings Snapshot Enova International (ENVA) has capped FY 2025 with fourth quarter revenue of US$412.9 million and basic EPS of US$3.19, while trailing twelve month EPS sits at US$12.25 on revenue of about US$1.5 billion. The company has seen quarterly revenue move from US$323.5 million in Q3 2024 to US$412.9 million in Q4 2025, with basic EPS over that stretch ranging from US$1.64 to just above US$3 per share. With net margin at 20.7% over the last year versus...

Versant Media Group: Key recent moves and performance snapshot Versant Media Group (VSNT) has drawn fresh attention after recent trading left the stock around $33.59, with a one-month return of about a 28% decline and year-to-date performance also down roughly 28%. See our latest analysis for Versant Media Group. The recent 1-day and 7-day share price returns of 1.27% and 3.55% sit against a 30-day and year to date share price return of about a 28% decline. This suggests short term momentum...

Genesem Inc.'s ( KOSDAQ:217190 ) price-to-earnings (or "P/E") ratio of 32.2x might make it look like a strong sell...

Starbucks (SBUX) opened fiscal Q1 2026 with revenue of US$9.9b and basic EPS of US$0.26, alongside net income of US$293.3m, setting the tone for how investors assess the latest quarter against a year of softer profitability. Over the past year, the company has seen quarterly revenue range from US$8.8b to US$9.6b and EPS move between US$0.12 and US$0.69, while trailing twelve month figures sit at US$37.7b of revenue, EPS of US$1.20 and net income of US$1.37b. With the trailing net margin at 5%...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

John Marshall Bancorp (JMSB) just turned in another steady quarter for FY 2025, with Q3 revenue of about US$15.9 million and basic EPS of roughly US$0.38 on net income of US$5.4 million. The bank has seen revenue move from US$13.4 million and EPS of about US$0.30 in Q3 2024 to US$15.9 million and EPS of roughly US$0.38 in Q3 2025. Trailing 12 month EPS sits around US$1.41 on net income of about US$20.0 million, which highlights a story where higher earnings and firmer profitability metrics...

Investors may be wondering whether Antero Resources at around US$34.46 is offering good value right now or whether most of the potential upside has already been reflected in the price. The stock has been fairly flat in the short term, with a 0.6% move over the last week, a 0.4% decline over the last month, and a modest 0.7% return year to date. Over the last year the return sits at a 7.7% decline and the 3-year return at 23.4%. Over a 5-year period the share price change has been very large...

Sang-A Frontec Co.,Ltd. ( KOSDAQ:089980 ), is not the largest company out there, but it saw a double-digit share price...

Taysha Gene Therapies recently reported progress in its TSHA-102 gene therapy program for Rett syndrome, including dosing the first patient in the pivotal REVEAL trial and securing FDA alignment on the study design, while senior executives disclosed significant insider stock sales. This combination of clinical and regulatory milestones with insider activity offers a rare window into both the program’s momentum and leadership’s capital decisions. We’ll now examine how the FDA’s alignment on...

NVR (NVR) has just posted its FY 2025 third quarter numbers, with revenue of US$2.6b and basic EPS of US$119.26, set against a trailing 12 month EPS of US$484.98 and revenue of US$10.6b. Over recent quarters, revenue has moved from US$2.6b in Q2 2025 and US$2.4b in Q1 2025, alongside basic EPS of US$114.52 and US$100.41 respectively. This gives investors a clear read on the run rate as they weigh the latest figures against a net profit margin that has eased from 15.9% to 13.5% over the past...

NANO (KOSDAQ:187790) has had a great run on the share market with its stock up by a significant 86% over the last three...

Orrstown Financial Services (ORRF) has rounded out FY 2025 with fourth quarter revenue of US$64.8 million and basic EPS of US$1.12, alongside trailing twelve month revenue of US$252.1 million and EPS of US$4.21. Over the last few quarters, revenue has moved from US$60.1 million in Q4 2024 to US$64.8 million in Q4 2025, while quarterly basic EPS has shifted from US$0.72 to US$1.12 over the same period. This frames a year in which trailing net income reached US$80.9 million. With a trailing net...

Key Insights HB SOLUTION's significant individual investors ownership suggests that the key decisions are influenced by...

Centerra Gold (TSX:CG) is back in focus after securing extended permits and a 10% planned throughput increase at its Mount Milligan mine, along with updated resource figures and a new preliminary economic assessment (PEA) for the Kemess project in British Columbia. See our latest analysis for Centerra Gold. Those permitting wins and the Kemess PEA land against a backdrop of strong recent momentum, with a 30 day share price return of 37.95% and a 1 year total shareholder return above 200%,...

German American Bancorp (GABC) just posted its FY 2025 fourth quarter numbers, reporting revenue of US$94.0 million and EPS of US$0.95, supported by quarterly net income of US$35.7 million. The bank’s revenue moved from US$64.5 million in Q4 2024 to US$94.0 million in Q4 2025, while quarterly EPS increased from US$0.78 to US$0.95 over the same period, indicating a notably different earnings profile than a year ago. With a trailing 12 month net profit margin of 32% and a P/E above sector...

Key Insights The considerable ownership by public companies in ITM Semiconductor indicates that they collectively have...